ABMD 34.24 Abiomed $ABMD Hit a 52 week high of 34.55

New Post Public Reply Private Reply Replies (0) Message Board

Nov 20, 2014 at 10:02 AM

ABMD 34.24 Abiomed $ABMD Hit a 52 week high of 34.55 Closing the day 09:45 at 34.24 -0.38 -1.10% With a day low of 34.09 and a total volume of 8,524.

ABMD Recent Posts: http://investorshangout.com/Abiomed-ABMD-53201/

ABMD Abiomed Recent Headline News

Abiomed and Area Colleges to Host Life Sciences Career Seminars for Growing Number of Student Veterans
GlobeNewswire - 2 hrs 1 min ago
The MedTech and BioTech Veterans Program (MVP) announced today it will host two Student Veteran Re-careering Seminars for student service members, veterans and graduates interested in pursuing careers in the life sciences.
ABMD: 34.17 (-0.45)

ABIOMED Has Returned 40.9% Since SmarTrend Recommendation (ABMD)
Comtex SmarTrend(R) - Wed Nov 19, 9:44AM CST
SmarTrend identified an Uptrend for ABIOMED (NASDAQ:ABMD) on October 28th, 2014 at $24.67. In approximately 3 weeks, ABIOMED has returned 40.94% as of today's recent price of $34.77.
ABMD: 34.17 (-0.45)

ABIOMED Earnings In Retrospect: Up 6.1% in the Last 18 Days (ABMD)
Comtex SmarTrend(R) - Mon Nov 17, 12:42PM CST
When ABIOMED (NASDAQ:ABMD) reported earnings 18 days ago on October 30th, 2014, analysts, on average, expected the company to report earnings of $0.02 on sales of $50.1 million. ABIOMED actually reported earnings of $0.09 per share on sales of $51.9 million, beating EPS estimates by $0.07 and beating revenue estimates by $1.8 million. Shares of ABIOMED have climbed from $31.35 to $33.25, representing a gain of 6.1% since the company reported earnings 18 days ago.
ABMD: 34.17 (-0.45)

Abiomed to Present at the Jefferies 2014 Global Healthcare Conference
GlobeNewswire - Mon Nov 17, 7:18AM CST
Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Robert L. Bowen, Vice President & Chief Financial Officer, will present at the Jefferies 2014 Global Healthcare Conference on November 20, 2014 at 10:40 a.m. GMT. The conference will be held at The Waldorf Hilton London in London, UK.
ABMD: 34.17 (-0.45)

Varian Medical (VAR) Down to Strong Sell on Dismal Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 2:20PM CST
On Nov 14, 2014, Zacks Investment Research downgraded Varian Medical Systems (VAR) to a Zacks Rank #5 (Strong Sell).
ABMD: 34.17 (-0.45), VAR: 87.56 (-0.10), EW: 122.92 (-2.67), ANGO: 16.88 (-0.16)

ABIOMED (ABMD) Stock: Moving Average Crossover Alert - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 6:33AM CST
ABIOMED (ABMD) Stock: Moving Average Crossover Alert
ABMD: 34.17 (-0.45)

Thoratec (THOR) Down to Strong Sell on Growing Headwinds - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 12:20PM CST
On Nov 11, 2014, Zacks Investment Research downgraded Thoratec Corp. (THOR) to a Zacks Rank #5 (Strong Sell).
ABMD: 34.17 (-0.45), EW: 122.92 (-2.67), THOR: 30.00 (-0.02), ANGO: 16.88 (-0.16)

Abiomed (ABMD) Hits 52-Week High on Strong Q2 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:10AM CST
Shares of Abiomed, Inc. (ABMD) have been on the rise since it reported impressive second-quarter fiscal 2015 (ended Sep 30, 2014) results on Oct 30.
ABMD: 34.17 (-0.45), FLDM: 29.85 (-0.53), GMED: 22.37 (-0.28), ANGO: 16.88 (-0.16)

ABIOMED Shares Up 34.3% Since SmarTrend's Buy Recommendation (ABMD)
Comtex SmarTrend(R) - Wed Nov 12, 9:15AM CST
SmarTrend identified an Uptrend for ABIOMED (NASDAQ:ABMD) on October 28th, 2014 at $24.67. In approximately 2 weeks, ABIOMED has returned 34.28% as of today's recent price of $33.13.
ABMD: 34.17 (-0.45)

Mettler-Toledo (MTD) Tops Q3 Earnings on Revenue Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 8:34AM CST
Mettler-Toledo International Inc. (MTD) reported adjusted earnings per share (EPS) of $2.95 for the third quarter of fiscal 2014, which beat the Zacks Consensus Estimate of $2.86. Adjusted EPS also improved 13% from the year-ago quarter.
ABMD: 34.17 (-0.45), FLDM: 29.85 (-0.53), ANGO: 16.88 (-0.16), MTD: 291.01 (-1.40)

Roka Bioscience (ROKA) in Focus: Stock Surges 19.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:11AM CST
Roka Bioscience, Inc. (ROKA) was a big mover last session, as the company saw its shares rise over 19% on the day.
ABMD: 34.17 (-0.45), ROKA: 3.94 (unch), EW: 122.92 (-2.67), ANGO: 16.88 (-0.16)

OTC Daily Alert Stock Watch - ABIOMED, Inc. (NASDAQ: ABMD)
WorldStockWire - Mon Nov 10, 12:30PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ABMD: 34.17 (-0.45)

Volcano Posts Narrower-than-Expected Q3 Loss, Guides Low - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 10:10AM CST
Despite Volcano (VOLC) provided disappointing revenue guidance for 2014 on account of expected negative foreign exchange impact, management expects accelerated profitability over the near term.
ABMD: 34.17 (-0.45), VOLC: 10.94 (+0.04), EW: 122.92 (-2.67), ANGO: 16.88 (-0.16)

Strength Seen in DexCom (DXCM): Stocks Gains 14.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:46AM CST
DexCom (DXCM) was a big mover last session, with shares rising over 14% on the day.
ABMD: 34.17 (-0.45), DXCM: 50.59 (+0.11), EW: 122.92 (-2.67), ANGO: 16.88 (-0.16)

VYCOR: "On the Cusp of the Next Big Healthcare Trend"
ACCESSWIRE - Mon Nov 10, 8:23AM CST
Vycor: "On the Cusp of the Next Big Healthcare Trend"
MDVN: 108.07 (-1.01), ABMD: 34.17 (-0.45), JNJ: 107.98 (-0.78), AMGN: 162.50 (-0.14), EXAS: 22.57 (-0.04), ARAY: 7.14 (-0.07), HOLX: 26.14 (-0.15), PBYI: 221.01 (-2.31)

Update: Abiomed's Q2 Fiscal 2015 Earnings Remained Impressive
Andy Batts - at Seeking Alpha - Sat Nov 08, 4:40PM CST

ABMD: 34.17 (-0.45)

Hologic Beats Q4 Earnings, Sales as All Segments Gain - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 1:50PM CST
Hologic (HOLX) entered into an amended license agreement with Roka Bioscience, which earned a one-time revenue benefit of $20.1 million for Hologic
ABMD: 34.17 (-0.45), DXCM: 50.59 (+0.11), ANGO: 16.88 (-0.16), HOLX: 26.14 (-0.15)

Thoratec Q3 Earnings & Revenues Lag Estimates, Down Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:00AM CST
Following the earnings release, shares of Thoratec Corp. (THOR) declined approximately 3.5% to close at $26.10 yesterday.
ABMD: 34.17 (-0.45), CYNO: 26.27 (-0.21), THOR: 30.00 (-0.02), ANGO: 16.88 (-0.16)

Abiomed (ABMD) Upgraded From Hold to Buy
at The Street - Fri Nov 07, 8:07AM CST
Abiomed (ABMD) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B.
ABMD: 34.17 (-0.45)

Foundation Medicine Slumps: FMI Tumbles 9.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:59AM CST
Foundation Medicine has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
ABMD: 34.17 (-0.45), DXCM: 50.59 (+0.11), FMI: 24.28 (+0.14), ANGO: 16.88 (-0.16)

Abiomed (ABMD) Stock Research Links

ABMD Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AAR's Agreement with Airbus Elevates Repair Capabilities

A Strategic Play in the Aviation Game Alright, if you've been scanning the skies of the aviation aftermarket lately, AAR's recent maneuver ought to catch your eye. These folks have clinched a multi-year deal with Airbus Avionics, paving the runway for expanded radome repair capabilities. For those less acquainted with the inner workings of aviation, radomes protect those...

Cohen & Steers Sees Steady Rise in October AUM

Market Pushes Cohen & Steers Forward It's been a wild ride for financial managers lately, and Cohen & Steers, Inc. (NYSE: CNS) isn't exempt from the rollercoaster. As of October 31, 2026, they've reported assets under management (AUM) climbing to $99.6 billion—thanks to a hefty market appreciation of $4 billion. Not too shabby when you're dealing with the...

AppLovin Faces Fraud Lawsuit, Investors Alerted

AppLovin's Lawsuit: A Wake-Up Call for Investors The market never forgets, even if some investors might wish reality wasn’t so harsh. On the chopping block this time is AppLovin Corporation (NASDAQ: APP). Seems like their fairy tale with AI turned into a courtroom drama, one that’s throwing a real curveball on those rosy earnings expectations. What's the Case All...

Foundayo Aims to Revolutionize Sleep Apnea Treatment

Revolution in Sleep Health The paper has officially announced a promising shift in sleep apnea treatment. Eli Lilly's Foundayo, revealed through a Phase 3 clinical program, is looking to tackle obstructive sleep apnea (OSA) with unprecedented potential. Forget the traditional methods—this small molecule GLP-1 receptor agonist could be a game changer for folks plagued by...

Pak Mail Expands: Franchisee Adds Location Fast

Franchise Growth: Adding Another Brick When's the last time you heard of a franchisee eager enough to nab a second location? Well, that's exactly what's happening with Manny Zussman, who’s decided his Boulder Pak Mail outlet wasn’t keeping him busy enough. This entrepreneurial spirit's on full display as he's launching another Pak Mail over in Westminster, Colorado....

AssureTrace Brings Graham Clark on Board for Growth

Serialization's Fresh Outlook So, here we are—with one sharp mover joining the pack. Graham Clark is stepping into AssureTrace as the Chief Revenue Officer and Business Director. Another suit hopping on yet another board, but this time, it's got some seasoning we're looking at. Clark's packing over 23 years of serialization hustle, and that's not small change in the...

Upsher-Smith Rolls Out New Eye Solutions, Impacts Market

Upsher-Smith's Bold Move in Ophthalmics Right out of Maple Grove, Minnesota, Upsher-Smith Laboratories is shaking up the eye care scene with the launch of two strengths of Brimonidine Tartrate Ophthalmic Solution. We're talking 0.1% and 0.15%, folks. This ain't just a dribble in the ocean—these products are sailing into a $115 million market arena, according to IQVIA....

Navigating Simultaneous Home Buy and Sell Strategies

Juggling Two Housing Transactions You ever tried juggling chainsaws? That's what buying and selling your home at the same time can feel like. Selling First: Playing It Safe Some folks swear by selling their current home first, and there's good reason. It locks in your financial windfall, giving you a clear picture of your down payment and affordability. No more guessing...

Rainmaker's Cloud Seeding Milestone: Big Leap or Hype?

Pioneering Cloud Seeding: Rainmaker's Big Talk Mornings like this, I find myself wondering if we're still all buying snake oil—or if the future just landed in our laps. Rainmaker Technology Corporation just dropped what might be a game-changer or a grand illusion for those of us with a finger on the pulse of water tech. Their study in 'Atmosphere' paints a picture of...

Palmdale Expands Reach with Tri-County Acquisition

Fueling Up a New Chapter in Florida Once in a blue moon, you see a move that just clicks—and Palmdale Oil snapping up Tri-County Oil Distributors is that kind of slick deal. We're not talking about some Wall Street high-flyer here—this is down-to-earth business in North Central Florida, where local ties and trust still mean something. Why Tri-County Fits the Bill If...